Primary ADT in treatment of elderly men with organ-confined prostate cancer

One really has to wonder whether we are still treating elderly men, initially diagnosed with organ-confined prostate cancer, with first-line or “primary” androgen deprivation therapy ADT)! And if we are, why on Earth is that? … READ MORE …

Risk, prostate cancer, and being 70 to 80 years of age

So a relatively new article in Reviews in Urology caught your Sitemaster’s eye this morning — and worried him because it seemed to be communicating a conclusion of questionable accuracy, which we will explore below. And if we have misinterpreted the data provide in the paper, we are more than willing to be corrected. … READ MORE …

Treating metastatic prostate cancer in very elderly men: a review

A helpful review article on the treatment of metastatic and metastatic, castration-resistant prostate cancer (mCRPC) in very elderly men appears in last month’s issue of Clinical Interventions in Aging. … READ MORE …

Lower dosing of abiraterone acetate in treatment of elderly prostate cancer patients

A group of Italian clinicians and researchers have reported that low-dose abiraterone acetate along with very low-dose prednisone appears to be both effective and safe in the treatment of elderly patients between 85 and 93 years of age with castration-resistant prostate cancer (CRPC). … READ MORE …

Management of elderly men with low- and very low-risk prostate cancer

In a newly published article in the American Journal of Clinical Oncology, Mishra et al. have attempted to assess the application of immediate, first-line treatment among older men with favorable-risk prostate cancer. … READ MORE …

Is mass prostate cancer screening even ethical in men ≥ 65 years of age?

Now here’s a new perspective on the value of widespread prostate cancer screening from one of the founders of Prostate Cancer Awareness Week — Dr. David Crawford of the University of Colorado Health Science Center in Denver, CO  (who is also the Chairman of the Prostate Conditions Education Council): … READ MORE …

Cancer (and prostate cancer) screening in the elderly

The value of regular testing of increasingly elderly men and women for risk of cancer is controversial. However, a new paper in the Archives of Internal Medicine has certainly added to our knowledge of just how widespread such testing may be … at least in the USA. … READ MORE …

Age-related diagnosis with M1 disease and age-related prostate cancer-specific mortality rates

According to a media release from the University of Rochester, a new study suggests that “men age 75 and older are diagnosed with late-stage and more aggressive prostate cancer and thus die from the disease more often than younger men.” … READ MORE …

Excess deaths among some older men with prostate cancer

A population-based analysis of mortality data for men diagnosed with prostate cancer from three European nations suggests that “a small but important group of older patients” initially present with late stage prostate cancer and die rapidly as a consequence. … READ MORE …

The role of radical prostatectomy in older males with high-risk prostate cancer

Data reported earlier this year from the PIVOT study and separately from the long-term Scandinavian study have shown that the surgical treatment of prostate cancer in the patients enrolled in these trials showed no median prostate-cancer specific or overall survival benefit compared to watchful waiting in patients of > 65 years of age. … READ MORE …

Whole-gland cryoablation as first-line therapy in prostate cancer patients > 75 years of age

Based on data collected in the Cryo On-Line Database (COLD), Dhar et al. have just published an analysis of data from a total of 860 men, all over 75 years of age, who were treated with whole-gland cryoablation for clinically localized prostate cancer at times dating back to at least 1995. … READ MORE …

Frequency of PSA testing and immediacy of prostate cancer treatment among men over 70

Two recent publications have offered evidence that, at 10 and 12 years of follow-up, the potential benefits of surgical treatment for low- and intermediate-risk prostate cancer did not include any impact on overall survival for men of 65 years of age or more at the time of surgery. … READ MORE …

The management of high- and intermediate-risk prostate cancer in elderly males

Overall life expectancy of men in the US continues to rise. As a consequence, the way we treated localized prostate cancer in men of ≥ 70 years of age in 1990 will probably not be relevant or appropriate to the way we need to treat such men in 2020 (or perhaps even today). … READ MORE …

International recommendations on treatment of “older” men

A Prostate Cancer Task Force of the International Society of Geriatric Oncology (SIOG) has just issued new recommendations on the management of prostate cancer in “older men” (by which the task force means men of more than 70 years of age). … READ MORE …

Post-treatment mortality of elderly men with high-risk prostate cancer

New data from a series of > 700 elderly patients with high-risk prostate cancer suggests that aggressive combination therapy for such men is associated with a reduced risk for prostate cancer-specific mortality. … READ MORE …